<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018846</url>
  </required_header>
  <id_info>
    <org_study_id>CHRD0518</org_study_id>
    <nct_id>NCT04018846</nct_id>
  </id_info>
  <brief_title>The Future of Revascularization Using a Bioprotec Graft</brief_title>
  <acronym>REVATEC</acronym>
  <official_title>The Future of the Revascularization Using a Bioprotec Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier René Dubos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier René Dubos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is the rate assessment of rescued limbs, one year after a
      BIOPROTEC vascular graft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BIOPROTEC grafts are controverted: they are useful in some cases, but they are known as
      frequently broken or thrombosed. However they are always posed in a complicated situations,
      in a fragile patients who have ever had many of revascularizations or in an infectious state
      (which is supportive of the pseudoaneurysm and thrombosis) Despite the frequent use of this
      graft in France, the results have never been published.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The Limb rescue rate one year after a BIOPROTEC graft</measure>
    <time_frame>Two years</time_frame>
    <description>Usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular doctor in 1 month, 6 months, 12 months, 18 months and 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The revascularization permeability rate</measure>
    <time_frame>Two years</time_frame>
    <description>Usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular doctor in 1 month, 6 months, 12 months, 18 months and 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amputation rate</measure>
    <time_frame>Two years</time_frame>
    <description>Usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular doctor in 1 month, 6 months, 12 months, 18 months and 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection resistance rate</measure>
    <time_frame>Two years</time_frame>
    <description>Usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular doctor in 1 month, 6 months, 12 months, 18 months and 2 years</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Revascularization using a BIOPROTEC Graft</intervention_name>
    <description>It is about a routine care study not changing the usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular Doctor in 1 month, 6 months, 12 months, 18 months and 2 years.</description>
    <other_name>BIOPROTEC Vascular Graft</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Grafted patient with a vascular BIOPROTEC graft in case of a Peripheral artery disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ Eighteen years old.

          -  Critical ischemia (Phase 4-6 of Rutherford): no saphenous equipment for the vascular
             reconstruction; at least one leg axis permeable.

        Exclusion Criteria:

          -  Pregnant woman.

          -  Patient with an acute ischemia.

          -  Patient with an exceeded ischemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel DAVAINE, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Pitié Salpêtrière Vascular Surgery Service</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maryline DELATTRE</last_name>
    <phone>0033130754131</phone>
    <email>maryline.delattre@ght-novo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique DA COSTA</last_name>
    <phone>0033130755069</phone>
    <email>veronique.dacosta@ght-novo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cntre Hospitalier René Dubos</name>
      <address>
        <city>Cergy-Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryline DELATTRE</last_name>
      <phone>0033130754131</phone>
      <email>maryline.delattre@ght-novo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Véronique DA COSTA</last_name>
      <phone>0033130755069</phone>
      <email>veronique.dacosta@ght-novo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Eric Cheysson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Graft</keyword>
  <keyword>Vein</keyword>
  <keyword>Artery</keyword>
  <keyword>Limb</keyword>
  <keyword>Amputation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

